Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
Jul 1 LLY Lilly in deal with Radionetics Oncology on radiopharmaceuticals development
Jul 1 PFE A standard approach to drug development for accessing the globe
Jul 1 LLY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 PFE 2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
Jul 1 AMED Amedisys gains as UnitedHealth to sell some assets to gain regulatory approval
Jul 1 LLY Eli Lilly Soars To 52-Week High: Can The Momentum Continue?
Jul 1 AMED UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
Jul 1 PFE Should You Expect Upside Potential For Pfizer (PFE)?
Jul 1 LGND Lifecore Biomedical Announces Cooperation Agreement with 22NW
Jul 1 LLY Nvidia Among Biggest Stock Market Winners In 2024, But This Is No. 1
Jul 1 LLY Eli Lilly & Co (NYSE:LLY): Jim Cramer’s Best Weight Loss Stock Pick for 2024
Jul 1 LLY Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
Jul 1 PFE Cyrus Taraporevala Elected to Pfizer’s Board of Directors
Jul 1 LLY Atossa Therapeutics updates protocol for breast cancer treatment trial
Jul 1 BIIB 10 clinical trials to watch in the second half of 2024
Jul 1 LLY 10 clinical trials to watch in the second half of 2024
Jul 1 LLY Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
Jun 30 LLY 5 Reasons Eli Lilly Just Keeps Rising
Jun 30 LLY 2 Top Healthcare Stocks to Buy in June
Jun 30 LLY 3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags